Premium
Evaluation of ICL670, a Once‐Daily Oral Iron Chelator in a Phase III Clinical Trial of β‐Thalassemia Patients with Transfusional Iron Overload
Author(s) -
GALANELLO RENZO
Publication year - 2005
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1345.021
Subject(s) - medicine , osteoporosis , osteopenia , thalassemia , calcitonin , endocrinology , diabetes mellitus , gastroenterology , vitamin d and neurology , bone mineral
A bstract : Osteoporosis and osteopenia are frequent complications of thalassemia major (TM) and intermedia (TI). Osteoporosis was found in 23/25 patients with TI and in 115/239 patients with TM. In TM, no association was found with specific polymorphisms in candidate genes (vitamin D receptor, estrogen receptor, calcitonin receptor, and collagen type 1 alpha 1). Osteoporosis in TM female was strongly associated with primary amenorrhea (P < .0001), while in male patients with TM hypogonadism was not significantly related to BMD ( P = .0001 ). Low BMD was also associated with cardiomiopathy ( P = .01 ), diabetes mellitus ( P = .0001 ), chronic hepatitis ( P = .0029 ), and increased ALT ( P = .01 ).